ClariVest Asset Management LLC Acquires 8,347 Shares of Ligand Pharmaceuticals Inc. (LGND)

Share on StockTwits

ClariVest Asset Management LLC boosted its holdings in Ligand Pharmaceuticals Inc. (NASDAQ:LGND) by 35.9% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 31,598 shares of the biotechnology company’s stock after purchasing an additional 8,347 shares during the period. ClariVest Asset Management LLC’s holdings in Ligand Pharmaceuticals were worth $4,288,000 at the end of the most recent reporting period.

Other institutional investors have also bought and sold shares of the company. Vanguard Group Inc. lifted its stake in Ligand Pharmaceuticals by 3.3% in the third quarter. Vanguard Group Inc. now owns 2,090,137 shares of the biotechnology company’s stock worth $573,721,000 after purchasing an additional 66,789 shares during the last quarter. Fisher Asset Management LLC increased its position in shares of Ligand Pharmaceuticals by 55.1% in the fourth quarter. Fisher Asset Management LLC now owns 66,105 shares of the biotechnology company’s stock valued at $8,970,000 after acquiring an additional 23,486 shares during the period. Woodstock Corp increased its position in shares of Ligand Pharmaceuticals by 4.6% in the fourth quarter. Woodstock Corp now owns 69,759 shares of the biotechnology company’s stock valued at $9,466,000 after acquiring an additional 3,051 shares during the period. Rehmann Capital Advisory Group increased its position in shares of Ligand Pharmaceuticals by 26,645.0% in the third quarter. Rehmann Capital Advisory Group now owns 93,875 shares of the biotechnology company’s stock valued at $342,000 after acquiring an additional 93,524 shares during the period. Finally, Pacer Advisors Inc. purchased a new position in shares of Ligand Pharmaceuticals in the third quarter valued at about $368,000.

LGND stock opened at $120.44 on Thursday. Ligand Pharmaceuticals Inc. has a 12-month low of $98.56 and a 12-month high of $278.62. The stock has a market capitalization of $2.56 billion, a price-to-earnings ratio of 19.18, a PEG ratio of 1.17 and a beta of 1.40. The company has a debt-to-equity ratio of 1.09, a quick ratio of 10.50 and a current ratio of 10.59.

Ligand Pharmaceuticals (NASDAQ:LGND) last released its quarterly earnings data on Thursday, February 7th. The biotechnology company reported $1.70 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.22 by $0.48. Ligand Pharmaceuticals had a net margin of 57.00% and a return on equity of 26.00%. The firm had revenue of $59.59 million for the quarter, compared to analysts’ expectations of $52.58 million. During the same quarter in the previous year, the company earned $1.31 earnings per share. The company’s revenue for the quarter was up 18.1% compared to the same quarter last year. As a group, equities analysts predict that Ligand Pharmaceuticals Inc. will post 4.88 EPS for the current year.

A number of research firms have issued reports on LGND. HC Wainwright restated a “buy” rating and issued a $281.00 price objective on shares of Ligand Pharmaceuticals in a research report on Monday, November 5th. BidaskClub cut shares of Ligand Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Friday, October 19th. Zacks Investment Research upgraded shares of Ligand Pharmaceuticals from a “hold” rating to a “buy” rating and set a $126.00 price objective on the stock in a research report on Wednesday, January 23rd. Argus restated a “buy” rating and issued a $150.00 price objective (down previously from $200.00) on shares of Ligand Pharmaceuticals in a research report on Wednesday. Finally, ValuEngine upgraded shares of Ligand Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday, January 2nd. Two investment analysts have rated the stock with a sell rating, one has assigned a hold rating and six have issued a buy rating to the company’s stock. Ligand Pharmaceuticals currently has an average rating of “Hold” and a consensus price target of $216.57.

TRADEMARK VIOLATION NOTICE: This report was first published by Highlight Press and is the sole property of of Highlight Press. If you are viewing this report on another website, it was copied illegally and reposted in violation of U.S. and international copyright and trademark law. The original version of this report can be read at https://highlightpress.com/2019/02/14/clarivest-asset-management-llc-acquires-8347-shares-of-ligand-pharmaceuticals-inc-lgnd.html.

About Ligand Pharmaceuticals

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing and acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Promacta, an oral medicine that increases the number of platelets in the blood; Kyprolis and Evomela, which are used to treat multiple myeloma; Baxdela, a captisol-enabled delafloxacin-IV for the treatment of acute bacterial skin and skin structure infections; Nexterone, a captisol-enabled formulation of amiodarone; Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Carnexiv, which is indicated as replacement therapy for oral carbamazepine formulations; bazedoxifene for the treatment of postmenopausal osteoporosis; commercial pericardial repair and CanGaroo envelope extracellular matrix products; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta for non-small cell lung cancer.

Further Reading: Trading Strategy Methods for Individual Investors

Want to see what other hedge funds are holding LGND? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ligand Pharmaceuticals Inc. (NASDAQ:LGND).

Institutional Ownership by Quarter for Ligand Pharmaceuticals (NASDAQ:LGND)

Receive News & Ratings for Ligand Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ligand Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply